Wczytywanie kursów wyceny...
Prognoza
Średnia cena docelowa analityków wynosi 16,54 € (+63,76%). Mediana wynosi 16,36 € (+61,98%).
| Kupuj |
12 |
| Trzymaj |
1 |
| Sprzedaj |
0 |
Dyskusje w społeczności
Nie ma jeszcze dyskusji o tym aktywie.
Rozpocznij dyskusjęWiadomości Przejdź do aktualności
AbCellera presents strong phase‑II data on NK3R antibody ABCL635
AbCellera presented phase‑II results for the NK3R antibody ABCL635 at a healthcare conference showing about a twofold greater reduction in moderate to severe hot flashes versus approved small‑molecule therapies, with 37% of patients experiencing complete absence of hot flashes after a single dose. The safety profile has been unremarkable so far, notably without signs of elevated liver enzymes, and the company sees a potential multi‑billion‑dollar market for vasomotor symptoms. AbCellera plans to complete the ongoing phase‑II, hold discussions with regulators and start a pivotal phase‑III study in the second half of 2025; additional candidates and follow‑on programs are intended to supplement the pipeline. » Więcej na de.investing.com
Abcellera Biologics reaches 52-week high of $12.15 after clinical success and financing move
Abcellera Biologics shares rose to a 52-week high of $12.15 and are up about 172.5% year-to-date. Despite the rally, InvestingPro rates the stock as overvalued and the RSI indicates an overbought territory. In Q2 the company missed expectations with an adjusted loss of $0.18 per share and revenue of $4.1 million, but highlighted a strong cash position and announced a guaranteed public offering of $200 million. Positive top-line results from the Phase 2 study of ABCL635 prompted Truist to raise its price target from $12 to $30 while keeping a "Buy" rating. » Więcej na de.investing.com
Abcellera Biologics stock reaches 52-week high at $11.51
Abcellera Biologics shares climbed to a 52-week high of $11.51 after gaining 148% over the past year and 259% in the past six months. An InvestingPro analysis classifies the stock as overvalued and points to an overbought condition based on the RSI. In Q2 the company reported an adjusted loss of $0.18 per share and revenue of $4.1 million, both below analysts' expectations. AbCellera announced a guaranteed public offering of $200 million and simultaneously reported positive Phase‑2 results for ABCL635, after which Truist significantly raised its price target. » Więcej na de.investing.com
AbCellera plans public offering of $200 million at $9.75 per share
AbCellera is offering 17,435,897 common shares at $9.75 per share, as well as pre-funded warrants to purchase up to 3,076,926 shares at $9.74999 each, and expects gross proceeds of approximately $200 million before fees. The closing is expected to occur on Friday, subject to customary conditions. Net proceeds are intended to fund research, development and clinical advancement of the internal pipeline, including the ABCL635 program, as well as working capital and general corporate purposes. » Więcej na de.investing.com
Capital increase weighs on Abcellera stock after 35% jump
Abcellera announced a public offering of common shares and pre-funded warrants totaling $200 million, with proceeds to flow to the company. After the announcement the stock fell in after-hours trading as investors weighed the dilution against positive Phase‑2 data for ABCL635. Earlier the share price had risen about 35% after ABCL635 showed an average reduction in hot flashes of 83% at week four and analysts raised price targets. » Więcej na de.investing.com
Dane finansowe spółki
| (EUR) | wrzesień 2026 | YoY |
|---|---|---|
| Przychody | 9,39 mln | 23,09% |
| Zysk brutto | 9,39 mln | 23,09% |
| Zysk netto | -35,98 mln | 26,07% |
| EBITDA | -31,79 mln | 43,74% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 3,3 mld € |
Liczba akcji | 326,62 mln |
Maksimum/minimum z 52 tygodni | 13,65 € - 2,49 € |
| Dywidendy | Nie |
Beta | 1,19 |
C/Z (PE Ratio) | -23,17 |
PEG (PEG Ratio) | -1,59 |
C/WK (PB Ratio) | 3,33 |
C/S (PS Ratio) | 53,52 |
Profil spółki
AbCellera Biologics Inc. rozwija platformę do odkrywania przeciwciał. Jej w pełni zintegrowana, wspomagana sztuczną inteligencją platforma do odkrywania przeciwciał przeszukuje i analizuje bazę danych naturalnych układów odpornościowych, aby znajdować przeciwciała, które mogłyby zostać opracowane jako leki. Na dzień 31 grudnia 2021 roku spółka prowadziła 156 programów odkrywczych, które są zakończone, realizowane lub objęte umowami z 36 partnerami. AbCellera Biologics Inc. posiada umowę o współpracy badawczej i licencji z Eli Lilly and Company. Spółka została założona w 2012 roku i ma siedzibę w Vancouver w Kanadzie.
| Nazwa | AbCellera |
| CEO | Carl Hansen |
| Siedziba | Vancouver,
bc Kanada |
| Strona internetowa | |
| Sektor | Ochrona zdrowia |
| Branża | Biotechnologia |
| Debiut giełdowy | 11.12.2020 |
| Pracownicy | 562 |
Symbole giełdowe
| Giełda | Symbol |
|---|---|
NASDAQ | ABCL |
Frankfurt | 8QQ.F |
Düsseldorf | 8QQ.DU |
Hamburg | 8QQ.HM |
München | 8QQ.MU |
SIX | ABCL.SW |